相关临床试验
15
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
13.3%
尚未招募
8
53.3%
招募中
5
33.3%
暂无批准数据
- Zydus Lifesciences signed an MoU with Apollo Hospitals to offer the Shield Multi-Cancer Detection blood test across India, leveraging its exclusive agreement with Guardant Health. - The methylation-based blood test screens for 10 cancer types—including breast, colorectal, liver, and lung—in individuals aged 45 and older at average risk. - The Shield MCD test has received FDA Breakthrough Device Designation, recognizing its potential to improve cancer screening over existing options. - India recorded over 1.41 million new cancer cases and more than 900,000 deaths in 2022, yet screening rates remain low with wide regional disparities.
- Apollo Hospitals announces a Rs 573 crore investment to establish a 100-bed Comprehensive Oncology Centre in Gurugram featuring the Proteus One single gantry Proton Beam Therapy system. - The facility will mark Apollo's third proton therapy installation in India and is expected to serve an additional 350 patients annually by FY 2029. - Apollo aims to double its oncology business to over Rs 5,000 crore in the next 3-4 years through advanced treatments including proton therapy, robotics, immunotherapy, and CAR-T cell therapies. - The company simultaneously acquired IFC's 31% stake in Apollo Health and Lifestyle Ltd for Rs 1,254 crore to consolidate its healthcare portfolio operations.
- Apollo Hospitals and Siemens Healthineers have established a research collaboration to develop AI-enabled diagnostic and imaging solutions for liver disease management, focusing on quantitative ultrasound imaging and clinical decision support tools. - The partnership specifically targets Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects 9-32% of India's population and poses significant diagnostic challenges due to its underestimated prevalence. - The collaboration aims to enhance early detection of liver fibrosis through AI-driven disease progression models, enabling timely interventions and cost-effective screening for improved patient outcomes. - A Master Research Agreement was formalized in March 2025, with an addendum signed in July 2025 establishing the framework for collaborative research on diagnostic and interventional ultrasound imaging for liver care.
- Advent International has signed a definitive agreement to invest $175 million for a significant minority stake in Felix Pharmaceuticals, a Dublin-based company developing generic medicines for companion animals. - Felix Pharmaceuticals operates in the nascent animal health generics market where generic players hold less than 10% market share, providing substantial long-term growth opportunities. - The company has achieved rapid growth since its 2015 founding, securing 14 US FDA-approved products and serving 200 clients globally through its specialized veterinary manufacturing facilities. - The global animal pharmaceutical market is projected to reach $96.56 billion by 2033, growing at a CAGR of 5.13% from 2025 to 2033, driven by increasing pet ownership and healthcare spending.
- Elucidata and Sapien Biosciences announced a strategic partnership to convert Sapien's 300,000+ patient sample biobank into AI-ready, multimodal data products for drug discovery and diagnostic development. - The collaboration will focus initially on building AI models that infer genomic and transcriptomic insights from digital pathology images using NGS-annotated slides from Sapien's cancer biobank. - Sapien operates one of the top 10 biobanks globally with over 85,000 cancer patients and represents the largest integrated resource for Asian patient data across multiple disease areas. - The partnership aims to address underrepresentation in global omics datasets while accelerating precision medicine through synthetic clinicogenomic data generation.
